Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer.
colorectal cancer
epigenetics
genetic/epigenetic/immunological signature
immune infiltrates
mutation
patient
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 Mar 2023
24 Mar 2023
Historique:
received:
30
12
2022
revised:
08
03
2023
accepted:
23
03
2023
medline:
14
4
2023
entrez:
13
4
2023
pubmed:
14
4
2023
Statut:
epublish
Résumé
A large body of clinical and experimental evidence indicates that colorectal cancer is one of the most common multifactorial diseases. Although some useful prognostic biomarkers for clinical therapy have already been identified, it is still difficult to characterize a therapeutic signature that is able to define the most appropriate treatment. Gene expression levels of the epigenetic regulator histone deacetylase 2 (
Identifiants
pubmed: 37046620
pii: cancers15071960
doi: 10.3390/cancers15071960
pmc: PMC10093005
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : VALERE: Vanvitelli per la Ricerca Program: Adip-Care
ID : ID263
Organisme : the Campania Regional Government Lotta alle Patologie Oncologiche, iCURE
ID : CUPB21c17000030007
Organisme : MUR (PRIN 2020)
ID : CW39SJ
Organisme : MISE: Nabucco
ID : 1682
Organisme : EU: BBMRI: CANSERV project
ID : 101058620
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Mol Cancer Ther. 2023 Jan 3;22(1):52-62
pubmed: 36343387
Med Sci (Basel). 2018 Apr 13;6(2):
pubmed: 29652830
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618962
J Gastrointest Oncol. 2015 Jun;6(3):296-306
pubmed: 26029457
Cancers (Basel). 2013 Jun 05;5(2):676-713
pubmed: 24216997
Oncoimmunology. 2017 Nov 6;7(2):e1390640
pubmed: 29308317
Gastroenterology. 2008 Nov;135(5):1457-9
pubmed: 18851967
Mol Med. 2015 Oct 27;21 Suppl 1:S25-31
pubmed: 26605644
Oncotarget. 2015 Jan 20;6(2):886-901
pubmed: 25473896
FEBS Lett. 2019 Sep;593(18):2574-2584
pubmed: 31254352
Int J Cancer. 2022 Nov 1;151(9):1586-1601
pubmed: 35666536
Trends Cancer. 2020 Jul;6(7):605-618
pubmed: 32610070
Int J Cancer. 2007 Jul 15;121(2):454-8
pubmed: 17373663
Oncol Rep. 2018 Jun;39(6):2455-2472
pubmed: 29565457
Mutat Res Genet Toxicol Environ Mutagen. 2022 Feb-Mar;874-875:503445
pubmed: 35151424
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Dig Dis Sci. 2009 Oct;54(10):2109-17
pubmed: 19057998
J Pharmacol Exp Ther. 2014 Jan;348(1):59-68
pubmed: 24218540
Nat Genet. 2006 May;38(5):566-9
pubmed: 16642021
Mol Oncol. 2007 Jun;1(1):26-41
pubmed: 19383285
Ther Adv Med Oncol. 2022 May 21;14:17588359221099347
pubmed: 35620236
EXCLI J. 2018 Jan 22;17:159-168
pubmed: 29743854
J Transl Med. 2018 Dec 12;16(1):350
pubmed: 30541551
Cancer Med. 2018 May;7(5):1578-1603
pubmed: 29658188
Front Pharmacol. 2022 Oct 19;13:983092
pubmed: 36339570
Theranostics. 2021 Mar 11;11(11):5365-5386
pubmed: 33859752
Cancers (Basel). 2021 May 27;13(11):
pubmed: 34072037
Cells. 2022 Nov 04;11(21):
pubmed: 36359889
Chin J Cancer. 2016 Jan 06;35:4
pubmed: 26738600
Evid Based Complement Alternat Med. 2022 Aug 9;2022:7264503
pubmed: 35982994
Oncologist. 2020 Mar;25(3):e460-e468
pubmed: 32162808
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15
pubmed: 18990764
Oncol Lett. 2018 Jul;16(1):9-18
pubmed: 29928381